Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MPL W515L Everolimus myelofibrosis sensitive detail...
MPL W515K Everolimus myelofibrosis sensitive detail...
Unknown unknown Ruxolitinib myelofibrosis not applicable detail...
MPL W515L MK2206 myelofibrosis sensitive detail...
MPL W515L CHZ868 myelofibrosis sensitive detail...
Unknown unknown SAR302503 myelofibrosis not applicable detail...
Unknown unknown XL019 myelofibrosis not applicable detail...
CALR L367fs SAR302503 myelofibrosis predicted - sensitive detail...
JAK2 V617F N/A myelofibrosis not applicable detail...
MPL W515L N/A myelofibrosis not applicable detail...
MPL W515K N/A myelofibrosis not applicable detail...
CALR mutant N/A myelofibrosis not applicable detail...
CALR L367fs N/A myelofibrosis not applicable detail...
CALR wild-type JAK2 wild-type MPL wild-type N/A myelofibrosis not applicable detail...
ASXL1 mutant N/A myelofibrosis not applicable detail...
EZH2 mutant N/A myelofibrosis not applicable detail...
IDH1 mutant N/A myelofibrosis not applicable detail...
IDH2 mutant N/A myelofibrosis not applicable detail...
SRSF2 mutant N/A myelofibrosis not applicable detail...
ASXL1 wild-type CALR mut N/A myelofibrosis not applicable detail...
ASXL1 mut CALR wild-type N/A myelofibrosis not applicable detail...
ASXL1 mut CALR mut N/A myelofibrosis not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01398462 Phase I CWP232291 Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Completed
NCT02251821 Phase II Fludarabine Tacrolimus Mycophenolate mofetil Busulfan Pacritinib Momelotinib Melphalan Methotrexate Ruxolitinib Cyclophosphamide JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Recruiting
NCT02421354 Phase II Nivolumab Study of Nivolumab in Patients With Myelofibrosis Terminated
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated
NCT02493530 Phase I Ruxolitinib + Umbralisib TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea Recruiting
NCT02528877 Phase I Fludarabine + Melphalan Ruxolitinib + Sirolimus + Tacrolimus Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis Withdrawn
NCT02530619 Phase I Alisertib Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia Active, not recruiting
NCT02564536 Phase I Pacritinib + Decitabine Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Withdrawn
NCT02718300 Phase II INCB050465 + Ruxolitinib A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Recruiting
NCT02966353 Phase II Ruxolitinib Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE) Recruiting
NCT03042689 Phase I Regorafenib Study of Regorafenib in Patients With Advanced Myeloid Malignancies Recruiting
NCT03065400 Phase II Pembrolizumab PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Recruiting
NCT03136185 Phase II IMG-7289 IMG-7289 in Patients With Myelofibrosis Recruiting
NCT03144687 Phase II Itacitinib + Ruxolitinib Itacitinib A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Recruiting
NCT03289910 Phase II Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Recruiting
NCT03326310 Phase I Azacitidine + Selumetinib Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia Recruiting
NCT03373877 Phase I PU-H71 + Ruxolitinib Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis Recruiting
NCT03755518 Phase III SAR302503 An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM) Recruiting